| | Variable | With TCP () | Without TCP () | value |
| | Mean age (yrs) | | | <0.001 | | Male, (%) | 758 (81.0) | 6614 (77.0) | 0.005 | | Platelet (×109/L) | 85 (74–94) | 174 (141–215) | <0.001 | | Creatinine (μmol/L) | 85 (72–103) | 81 (69–95) | <0.001 | | Total bilirubin (μmol/L) | 13.1 (9.8–17.2) | 10.9 (8.0–14.8) | <0.001 | | Hypertension, (%) | 514 (54.9) | 4949 (57.6) | 0.12 | | Diabetes mellitus, (%) | 273 (29.2) | 2409 (28.0) | 0.46 | | Atrial fibrillation, (%) | 54 (5.8) | 332 (3.9) | 0.005 | | Hyperlipidemia, (%) | 68 (7.2) | 714 (8.3) | 0.27 | | Chronic kidney disease, (%) | 55 (5.9) | 316 (3.7) | 0.001 | | Chronic liver disease, (%) | 18 (1.9) | 44 (0.5) | <0.001 | | Unstable angina, (%) | 265 (28.3) | 2330 (27.1) | 0.43 | | NSTEMI, (%) | 92 (9.8) | 813 (9.5) | 0.71 | | STEMI, (%) | 140 (15.0) | 1445 (16.8) | 0.15 | | Cardiogenic shock, (%) | 23 (2.5) | 145 (1.7) | 0.09 | | Congestive heart failure, (%) | 112 (12.0) | 856 (10.0) | 0.054 | | Prior cerebrovascular accident, (%) | 21 (2.2) | 234 (2.8) | 0.39 | | Prior PCI, (%) | 125 (13.4) | 1124 (13.1) | 0.81 | | Prior CABG, (%) | 8 (0.9) | 53 (0.6) | 0.39 | | IABP, (%) | 53 (5.7) | 397 (4.6) | 0.15 | | Stents placed (≥2), (%) | 278 (29.7) | 2329 (27.1) | 0.09 | | Arterial approach | | | 0.27 | | Radial, (%) | 843 (90.1) | 7844 (91.3) | | | Femoral, (%) | 47 (5.0) | 407 (4.7) | | | Both, (%) | 36 (3.8) | 237 (2.8) | | | Other, (%) | 10 (1.1) | 107 (1.2) | | | Periprocedural medicine | | | | | Aspirin, (%) | 903 (96.5) | 8449 (98.3) | <0.001 | | Clopidogrel, (%) | 907 (96.9) | 8321 (96.8) | 0.88 | | Ticagrelor, (%) | 41 (4.4) | 410 (4.8) | 0.59 | | Warfarin, (%) | 12 (1.3) | 116 (1.3) | 0.87 | | NOAC, (%) | 3 (0.3) | 27 (0.3) | 1.0 | | Tirofiban, (%) | 161 (17.2) | 1531 (17.8) | 0.64 | | Enoxaparin, (%) | 254 (27.1) | 2448 (28.5) | 0.39 |
|
|
